Anifrolumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interferon α/β receptor |
| Clinical data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6444H9964N1712O2018S44 |
| Molar mass | 145.12 kg/mol g·mol−1 |
Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.[2]
This drug was developed by MedImmune, which chose to move anifrolumab instead of sifalimumab into Phase III trials for lupus in 2015.[3][4][5]
Adverse effects
The most common adverse effect in the study was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[6]
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
- ^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
- ^ "Anifrolumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
- ^ "Anifrolumab". AdisInsight. Retrieved 31 July 2017.
- ^ H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |